BioSpace

Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor

Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupixent.

By BioSpace

1 min read
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights